This antitumor activity of IFN-γ is being challenged by emerging facts that no significant improvement for patients was observed in clinical trials of IFN-γ treatment for melanoma and a wide variety of solid tumors as well as leukemia [51], suggesting a dual role that may also favor tumor immune evasion. The gene discussed is IFNG; the disease is leukemia.